A groundbreaking clinical trial at Toronto’s Princess Margaret Cancer Centre could revolutionize how doctors monitor cancer patients after treatment. Researchers are investigating whether a simple blood test can detect microscopic traces of cancer that traditional imaging methods like CT scans cannot identify.
Dr. Lillian Siu, the lead investigator, is enrolling 7,000 patients who have completed their cancer treatments including radiation and chemotherapy. The study, named SHERLOCK, will analyze blood samples to find tiny amounts of tumor DNA that may indicate the disease is still present at a molecular level. Previous smaller studies worldwide have shown promising results, but large-scale evidence is needed to make this a standard medical practice.
The implications of this research are significant for cancer survivors. If the liquid biopsy shows positive results, patients could receive additional experimental treatments such as new immunotherapies to prevent recurrence. Conversely, a negative test could spare patients from unnecessary chemotherapy or radiation sessions, reducing harmful side effects while providing peace of mind.
Dr. Siu, who leads the Peter Gilgan Centre for Early Cancer Detection Research, understands the emotional toll that cancer follow-ups take on patients. She notes that many survivors live with constant anxiety about their cancer returning, experiencing fear at every scheduled scan. The SHERLOCK trial, which will follow participants for at least five years, aims to address this uncertainty while examining whether the test’s effectiveness varies across different cancer types.
The research has garnered support from the scientific community. Gillian Vandekerkhove, a University of British Columbia professor specializing in bladder cancer and liquid biopsies, praised the trial’s comprehensive approach. She emphasized that SHERLOCK will generate valuable data and biobank samples that researchers can continue to study for years to come.
